350 related articles for article (PubMed ID: 20005474)
1. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
Reil JC; Reil GH; Böhm M
Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
[TBL] [Abstract][Full Text] [Related]
2. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
4. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
6. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
Ferrari R; Ceconi C
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
[TBL] [Abstract][Full Text] [Related]
7. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
8. Limited role for ivabradine in the treatment of chronic heart failure.
Cullington D; Goode KM; Cleland JG; Clark AL
Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
[TBL] [Abstract][Full Text] [Related]
9. Ivabradine: beyond heart rate control.
Riccioni G; Vitulano N; D'Orazio N
Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
[TBL] [Abstract][Full Text] [Related]
10. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
11. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
Colin P; Ghaleh B; Monnet X; Hittinger L; Berdeaux A
J Pharmacol Exp Ther; 2004 Jan; 308(1):236-40. PubMed ID: 14569053
[TBL] [Abstract][Full Text] [Related]
12. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
Doesch AO; Celik S; Ehlermann P; Frankenstein L; Zehelein J; Koch A; Katus HA; Dengler TJ
Transplantation; 2007 Oct; 84(8):988-96. PubMed ID: 17989604
[TBL] [Abstract][Full Text] [Related]
13. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.
De Ferrari GM; Mazzuero A; Agnesina L; Bertoletti A; Lettino M; Campana C; Schwartz PJ; Tavazzi L
Eur J Heart Fail; 2008 Jun; 10(6):550-5. PubMed ID: 18486549
[TBL] [Abstract][Full Text] [Related]
14. [Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
Chichkanov GG; Tsorin IB
Eksp Klin Farmakol; 2013; 76(2):37-42. PubMed ID: 23631283
[TBL] [Abstract][Full Text] [Related]
15. Ivabradine: Current and Future Treatment of Heart Failure.
Thorup L; Simonsen U; Grimm D; Hedegaard ER
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
[TBL] [Abstract][Full Text] [Related]
16. I(f) inhibition in cardiovascular diseases.
Thollon C; Vilaine JP
Adv Pharmacol; 2010; 59():53-92. PubMed ID: 20933199
[TBL] [Abstract][Full Text] [Related]
17. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure.
McMahon WS; Holzgrefe HH; Walker JD; Mukherjee R; Arthur SR; Cavallo MJ; Child MJ; Spinale FG
J Am Coll Cardiol; 1996 Aug; 28(2):495-505. PubMed ID: 8800131
[TBL] [Abstract][Full Text] [Related]
18. Heart rate as a treatable cardiovascular risk factor.
Tardif JC
Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
[TBL] [Abstract][Full Text] [Related]
19. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction.
Sette A; Martino A; Lioy E; Calò L
J Cardiovasc Electrophysiol; 2010 Jul; 21(7):815-7. PubMed ID: 20233274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
